{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Electroporation+Device",
    "query": {
      "intervention": "Electroporation Device"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 50,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Electroporation+Device&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T11:34:32.411Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03499795",
      "title": "VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anal Neoplasm"
      ],
      "interventions": [
        {
          "name": "VGX-3100",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CELLECTRA™ 5PSP",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "Inovio Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2018-05-15",
      "completion_date": "2021-05-26",
      "has_results": true,
      "last_update_posted_date": "2023-07-14",
      "last_synced_at": "2026-09-04T11:34:32.411Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • New York, New York",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03499795"
    },
    {
      "nct_id": "NCT02163057",
      "title": "Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Cancer"
      ],
      "interventions": [
        {
          "name": "INO-3112",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CELLECTRA™-5P",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "Inovio Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2014-08-13",
      "completion_date": "2017-01-23",
      "has_results": true,
      "last_update_posted_date": "2021-01-22",
      "last_synced_at": "2026-09-04T11:34:32.411Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02163057"
    },
    {
      "nct_id": "NCT00685412",
      "title": "Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Papillomavirus Infections"
      ],
      "interventions": [
        {
          "name": "VGX-3100",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Inovio Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 18,
      "start_date": "2008-05",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2017-09-13",
      "last_synced_at": "2026-09-04T11:34:32.411Z",
      "location_count": 3,
      "location_summary": "Winston-Salem, North Carolina • Hopwood, Pennsylvania • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Hopwood",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00685412"
    },
    {
      "nct_id": "NCT02204098",
      "title": "Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Carcinoma",
        "Malignant Neoplasm of Breast"
      ],
      "interventions": [
        {
          "name": "Mammaglobin-A DNA Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Optional biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 27,
      "start_date": "2015-01-07",
      "completion_date": "2028-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-09-04T11:34:32.411Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02204098"
    },
    {
      "nct_id": "NCT03988283",
      "title": "Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Central Nervous System Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pediatric Recurrent Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "Personalized neoantigen DNA vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Papivax Biotech TDS-IM v2.0",
          "type": "DEVICE"
        },
        {
          "name": "Peripheral blood draw",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "Up to 25 Years"
      },
      "enrollment_count": 7,
      "start_date": "2024-10-02",
      "completion_date": "2031-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-05-07",
      "last_synced_at": "2026-09-04T11:34:32.411Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03988283"
    },
    {
      "nct_id": "NCT03181789",
      "title": "Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "p24CE1/2 pDNA Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "p55^gag pDNA Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IL-12 pDNA Adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 56,
      "start_date": "2017-10-18",
      "completion_date": "2020-04-29",
      "has_results": true,
      "last_update_posted_date": "2024-02-07",
      "last_synced_at": "2026-09-04T11:34:32.411Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Decatur, Georgia • Cleveland, Ohio",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03181789"
    },
    {
      "nct_id": "NCT02348320",
      "title": "Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Triple Negative Breast Cancer",
        "Triple-Negative Breast Cancer",
        "Triple Negative Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Personalized polyepitope DNA vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 18,
      "start_date": "2015-06-17",
      "completion_date": "2020-03-12",
      "has_results": false,
      "last_update_posted_date": "2020-07-01",
      "last_synced_at": "2026-09-04T11:34:32.411Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02348320"
    },
    {
      "nct_id": "NCT04336410",
      "title": "Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Coronavirus Infection"
      ],
      "interventions": [
        {
          "name": "INO-4800",
          "type": "DRUG"
        },
        {
          "name": "CELLECTRA® 2000",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Inovio Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2020-04-03",
      "completion_date": "2022-02-10",
      "has_results": false,
      "last_update_posted_date": "2022-04-15",
      "last_synced_at": "2026-09-04T11:34:32.411Z",
      "location_count": 3,
      "location_summary": "Lexington, Kentucky • Kansas City, Missouri • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04336410"
    },
    {
      "nct_id": "NCT03502785",
      "title": "INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "INO-5401",
          "type": "BIOLOGICAL"
        },
        {
          "name": "INO-9012",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "CELLECTRA® 2000",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Inovio Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2018-07-24",
      "completion_date": "2025-05-09",
      "has_results": true,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-09-04T11:34:32.411Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • Tampa, Florida • Baltimore, Maryland + 7 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03502785"
    },
    {
      "nct_id": "NCT03823131",
      "title": "Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Head and Neck Squamous Cell Carcinoma",
        "Recurrent Head and Neck Squamous Cell Carcinoma",
        "Unresectable Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "ImmunoPulse",
          "type": "DEVICE"
        },
        {
          "name": "Epacadostat",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "CORVax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tavokinogene telseplasmid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Chase Heaton, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2019-05-02",
      "completion_date": "2022-07-31",
      "has_results": true,
      "last_update_posted_date": "2023-05-09",
      "last_synced_at": "2026-09-04T11:34:32.411Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03823131"
    }
  ]
}